Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenna Yager

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Annals of Hepatology|May 13, 2019
Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patientsAlisha Ahmed, Christopher Schriever, Nicholas Britt, et al.
AIDS Patient Care and Stds|August 4, 2017
Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency VirusJenna Yager, John Faragon, Liam McGuey, et al.
Lancet (London, England)|March 14, 2025
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label studyVamshi Jogiraju, Pallavi Pawar, Jenna Yager, et al.
AIDS Research and Human Retroviruses|August 9, 2022
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming HormonesJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
AIDS Research and Human Retroviruses|November 16, 2020
Individualized Adherence Benchmarks for HIV Pre-Exposure ProphylaxisMustafa E Ibrahim, Jose R Castillo-Mancilla, Jenna Yager, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones StudyRobert M Grant, Marion Pellegrini, Patricia A Defechereux, et al.
AIDS Research and Human Retroviruses|July 11, 2022
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil FumarateJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
Transgender Health|February 5, 2024
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER TrialMichelle S Cespedes, Moupali Das, Jenna Yager, et al.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annals of Hepatology|May 13, 2019
Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patientsAlisha Ahmed, Christopher Schriever, Nicholas Britt, et al.
AIDS Patient Care and Stds|August 4, 2017
Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency VirusJenna Yager, John Faragon, Liam McGuey, et al.
Lancet (London, England)|March 14, 2025
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label studyVamshi Jogiraju, Pallavi Pawar, Jenna Yager, et al.
AIDS Research and Human Retroviruses|August 9, 2022
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming HormonesJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
AIDS Research and Human Retroviruses|November 16, 2020
Individualized Adherence Benchmarks for HIV Pre-Exposure ProphylaxisMustafa E Ibrahim, Jose R Castillo-Mancilla, Jenna Yager, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones StudyRobert M Grant, Marion Pellegrini, Patricia A Defechereux, et al.
AIDS Research and Human Retroviruses|July 11, 2022
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil FumarateJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
Transgender Health|February 5, 2024
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER TrialMichelle S Cespedes, Moupali Das, Jenna Yager, et al.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Pageof 2